ES2827953T3 - Medicamento externo para neurofibroma plexiforme difuso - Google Patents

Medicamento externo para neurofibroma plexiforme difuso Download PDF

Info

Publication number
ES2827953T3
ES2827953T3 ES16768422T ES16768422T ES2827953T3 ES 2827953 T3 ES2827953 T3 ES 2827953T3 ES 16768422 T ES16768422 T ES 16768422T ES 16768422 T ES16768422 T ES 16768422T ES 2827953 T3 ES2827953 T3 ES 2827953T3
Authority
ES
Spain
Prior art keywords
weight
sirolimus
external
concentration
external drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16768422T
Other languages
English (en)
Spanish (es)
Inventor
Mari Kaneda
Ichiro Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Application granted granted Critical
Publication of ES2827953T3 publication Critical patent/ES2827953T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16768422T 2015-03-23 2016-03-09 Medicamento externo para neurofibroma plexiforme difuso Active ES2827953T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015059041A JP6541124B2 (ja) 2015-03-23 2015-03-23 びまん性神経線維腫用の外用薬
PCT/JP2016/057330 WO2016152519A1 (ja) 2015-03-23 2016-03-09 びまん性神経線維腫用の外用薬

Publications (1)

Publication Number Publication Date
ES2827953T3 true ES2827953T3 (es) 2021-05-25

Family

ID=56978382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16768422T Active ES2827953T3 (es) 2015-03-23 2016-03-09 Medicamento externo para neurofibroma plexiforme difuso

Country Status (7)

Country Link
US (1) US10117857B2 (enExample)
EP (1) EP3275441B1 (enExample)
JP (1) JP6541124B2 (enExample)
CN (1) CN107708694A (enExample)
ES (1) ES2827953T3 (enExample)
HK (1) HK1250917A1 (enExample)
WO (1) WO2016152519A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131366A1 (en) * 2019-02-27 2020-09-03 Osaka University External preparation for vascular abnormality treatment
CN114555081A (zh) * 2019-10-16 2022-05-27 国立大学法人大阪大学 用于治疗癫痫或用于治疗自闭症谱系障碍的外用剂
CN113332228B (zh) * 2021-04-29 2023-03-31 杭州中美华东制药有限公司 一种西罗莫司凝胶制剂
DE102023119976A1 (de) * 2023-07-27 2025-01-30 Nobelpharma Co., Ltd. Rapamycin-haltige pharmazeutische zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
AU2006210787C1 (en) * 2005-02-02 2013-01-17 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
TR201807065T4 (tr) * 2006-02-02 2018-06-21 Novartis Ag Tüberöz sklerozis tedavisi.
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same

Also Published As

Publication number Publication date
US10117857B2 (en) 2018-11-06
EP3275441A1 (en) 2018-01-31
EP3275441B1 (en) 2020-08-12
US20180110759A1 (en) 2018-04-26
HK1250917A1 (zh) 2019-01-18
JP2016175884A (ja) 2016-10-06
CN107708694A (zh) 2018-02-16
EP3275441A4 (en) 2019-01-16
JP6541124B2 (ja) 2019-07-10
WO2016152519A1 (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
ES2473577T3 (es) Composición antioxidante que comprende galactomanano y N-acetil-ciste�na
ES2675228T3 (es) Preparaciones tópicas de vasoconstrictores y métodos para proteger a las células durante la quimioterapia y radioterapia del cáncer
Seo et al. Injectable intratumoral hydrogel as 5-fluorouracil drug depot
Lee et al. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo
US9717756B2 (en) Method of treating traumatic brain or spinal cord injury with biomembrane sealing agent and magnesium compounds
CN101678044B (zh) 用于治疗神经损伤的包括生物膜密封剂的组合物和使用方法
ES2827953T3 (es) Medicamento externo para neurofibroma plexiforme difuso
HU225967B1 (en) Process for producing of pharmaceutical compositions for the topical treatment of analgetic drug
ES2930254T3 (es) Composiciones y métodos para el tratamiento de heridas
ES2743740T3 (es) Aducto de ciclodextrina-panobinostat
ES2740958T3 (es) Composiciones de liberación controlada y sus procedimientos de uso
US10016422B2 (en) Nanocarrier drug delivery platform
ES2784557T3 (es) Formulaciones acuosas estables que comprenden unos principios activos poco solubles en agua
CN101933897B (zh) 注射用重组人血管内皮抑制素温度敏感性凝胶组合物
Bavarsad et al. The effect of topical quercetin loaded liposome on pressure ulcer healing in rats
JP2023538075A (ja) 長時間作用のインサイチュ形成／ゲル化組成物
US20220142990A1 (en) External preparation for treating a vascular anomaly
Taguchi et al. Evaluation of tumor tissue fixation effects of formulation modified Mohs pastes in mice and their water-absorbing properties
CN110721152B (zh) 一种治疗动物皮肤寄生虫、真菌感染的缓释组合物
CN106265112B (zh) 促进伤口愈合的药物或化妆用组合物
RU2794958C2 (ru) Композиция ранозаживляющего действия
BRPI0902144A2 (pt) processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam
Tapkir et al. FORMULATION AND EVALUATION OF NOVEL HYDROGEL BASED DRUG DELIVERY SYSTEM FOR RESVERATROL TARGETING GLIOBLASTOMA
PT1891940E (pt) Formulações intra-sinoviais de estanozolol
BR102016030321A2 (pt) hidrogel de alginato contendo vitaminas do complexo b, resveratrol e carvacrol para cicatrização de ferimentos cutâneos